Market Overview

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018


Webcast and Conference Call today at 4:30 p.m. ET

  • Royalty revenue for the quarter increased to $57.3 million, a
    quarter-to-quarter increase of 30%
  • Net income was $20.3 million, or $0.97 per diluted common share
  • Preliminary Phase 1 results demonstrate that RSV candidate EDP-938
    was generally safe and well tolerated and support its progression to
    Phase 2
  • Cash and marketable securities totaled $295.5 million at June 30,

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today reported
financial results for its fiscal third quarter ended June 30, 2018.

"Enanta continues to benefit from the increasing royalty income from
AbbVie's net sales of MAVYRET, the best-selling drug for hepatitis C,
which is funding development of our wholly owned programs in RSV, NASH,
PBC and HBV," commented Jay R. Luly, Ph.D., President and Chief
Executive Officer, Enanta. "With net sales of MAVYRET in the first half
of calendar and royalty year 2018 reaching over $1.75 billion, our
royalties on 50% of those sales have moved into higher royalty rate
tiers this quarter. In addition, in RSV we have completed dosing our
Phase 1 trial of EDP-938, and expect to report final results later this

Fiscal Third Quarter Ended June 30, 2018 Financial Results

Total revenue for the three months ended June 30, 2018 was $57.3
million, compared to $7.5 million for the three months ended June 30,
2017. The increase in revenue was due to an increase in royalties earned
on AbbVie's worldwide net sales of MAVYRET™/MAVIRET™
(glecaprevir/pibrentasvir), in major markets. For the three months ended
June 30, 2017, revenue consisted exclusively of royalties earned on
AbbVie's worldwide net sales of HCV regimens containing paritaprevir.

Research and development expenses totaled $28.5 million for the three
months ended June 30, 2018, compared to $15.4 million for the three
months ended June 30, 2017. The increase in research and development
expenses was primarily due to increased preclinical and clinical costs
associated with the progression of Enanta's wholly-owned R&D programs in
respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH)
and primary biliary cholangitis (PBC), as well as research efforts in
hepatitis B virus (HBV).

General and administrative expenses totaled $6.1 million for the three
months ended June 30, 2018, compared to $5.2 million for the three
months ended June 30, 2017. The increase in general and administrative
expenses was primarily due to an increase in headcount.

Enanta recorded income tax expense of $3.7 million for the three months
ended June 30, 2018, compared to an income tax benefit of $4.1 million
for the three months ended June 30, 2017. During the three months ended
June 30, 2018, income tax expense reflected the significant increase
in pre-tax income during the quarter, offset by the impact of excess tax
benefits from employee stock award activity. Enanta's estimated annual
effective tax rate for fiscal 2018 of 22.2 percent includes the impact
of a non-cash revaluation charge against deferred tax assets to reflect
the reduced federal corporate income tax rate as a result of the
enactment of the U.S. Tax Cuts and Jobs Act in December 2017, during the
first quarter of Enanta's current fiscal year.

Net income for the three months ended June 30, 2018 was $20.3 million,
or $0.97 per diluted common share, compared to a net loss of $8.4
million, or $(0.44) per diluted common share, for the corresponding
period in 2017.

Enanta's cash, cash equivalents and short-term and long-term marketable
securities totaled $295.5 million at June 30, 2018. This compares to a
total of $293.7 million at September 30, 2017. Enanta expects that its
current cash, cash equivalents and marketable securities, will be
sufficient to meet the anticipated cash requirements of its existing
business and development programs for the foreseeable future.

Development Programs and Business Review

Respiratory Syncytial Virus

  • Preliminary Phase 1 results demonstrate that EDP-938 was generally
    safe and well tolerated over a broad range of single and multiple
    doses with good pharmacokinetic (PK) data. Final results will be
    presented in the fourth calendar quarter of 2018.
  • A Phase 2 proof-of-concept challenge study in healthy adults
    inoculated with RSV is expected to begin in the fourth calendar
    quarter of 2018.


  • Enrollment continues in the ARGON-1 study for non-alcoholic
    steatohepatitis (NASH), and in the INTREPID study for primary biliary
    cholangitis (PBC) patients. We expect enrollment to continue
    throughout the year and into 2019.

Hepatitis B Virus

  • Enanta's HBV program continues to move ahead and has generated
    promising inhibitors of the core protein. Enanta is targeting the
    selection of an HBV candidate in the fourth calendar quarter of 2018.

Upcoming Events and Presentations

  • September 5-6, Baird 2018 Global Healthcare conference, New York
  • September 12-14, Morgan Stanley 16th Annual Global
    Healthcare Conference, New York
  • Enanta plans to issue its fiscal fourth quarter financial results
    press release, and hold a conference call regarding those results, on
    November 26, 2018.

Conference Call and Webcast Information
Enanta will host a
conference call and webcast today at 4:30 p.m. ET. To participate in the
live conference call, please dial (855) 840-0595 in the U.S. or (518)
444-4814 for international callers. A replay of the conference call will
be available starting at approximately 7:30 p.m. ET on August 7, 2018,
through 11:59 p.m. ET on August 9, 2018 by dialing (855) 859-2056 from
the U.S. or (404) 537-3406 for international callers. The passcode for
both the live call and the replay is 7278673. A live audio webcast of
the call and replay can be accessed by visiting the "Events and
Presentation" section on the "Investors" page of Enanta's website at

About Enanta
Enanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become a
leader in the discovery and development of small molecule drugs for the
treatment of viral infections and liver diseases. Two protease
inhibitors, glecaprevir and paritaprevir, discovered and developed
through Enanta's collaboration with AbbVie, have now been approved
around the world as part of AbbVie's regimens for the treatment of
hepatitis C virus (HCV) infection, sold under the tradenames MAVYRET™
(U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA
PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) and VIEKIRAX®
(paritaprevir/ritonavir/ombitasvir) (ex-U.S.).

Royalties from the AbbVie collaboration are helping to fund Enanta's
research and development efforts, which are currently focused on the
following disease targets: non-alcoholic steatohepatitis (NASH), primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV). Please visit
for more information.

Forward Looking Statements
This press release contains
forward-looking statements, including statements with respect to the
prospects for AbbVie's MAVYRET/MAVIRET regimen in HCV and Enanta's
resulting royalty revenues, as well as the prospects and timelines for
advancement of Enanta's earlier stage programs in NASH, PBC, RSV and
HBV. Statements that are not historical facts are based on management's
current expectations, estimates, forecasts and projections about
Enanta's business and the industry in which it operates and management's
beliefs and assumptions. The statements contained in this release are
not guarantees of future performance and involve certain risks,
uncertainties and assumptions, which are difficult to predict.
Therefore, actual outcomes and results may differ materially from what
is expressed in such forward-looking statements. Important factors and
risks that may affect actual results include: Enanta's revenues are
dependent upon the success of AbbVie's continuing commercialization
efforts for its HCV treatment regimens, primarily its new
MAVYRET/MAVIRET regimen; competitive pricing, market acceptance and
reimbursement rates for AbbVie's HCV treatment regimens compared to
competitive HCV products on the market; the discovery and development
risks of early stage discovery efforts in other disease areas such as
NASH, PBC, RSV and HBV; potential competition from the development
efforts of others in those other disease areas; Enanta's lack of
clinical development experience; Enanta's need to attract and retain
senior management and key scientific personnel; Enanta's need to obtain
and maintain patent protection for its product candidates and avoid
potential infringement of the intellectual property rights of others;
and other risk factors described or referred to in "Risk Factors" in
Enanta's most recent Form 10-Q for the quarter ended March 31, 2018 and
other periodic reports filed more recently with the Securities and
Exchange Commission. Enanta cautions investors not to place undue
reliance on the forward-looking statements contained in this release.
These statements speak only as of the date of this release, and Enanta
undertakes no obligation to update or revise these statements, except as
may be required by law.




(in thousands, except per share amounts)

Three Months Ended Nine Months Ended
June 30, June 30,
  2018     2017     2018     2017  
Revenue $ 57,262 $ 7,511 $ 139,420 $ 26,887
Operating expenses
Research and development 28,487 15,407 67,933 40,937
General and administrative   6,135     5,233     17,611     15,631  
Total operating expenses   34,622     20,640     85,544     56,568  
Income (loss) from operations 22,640 (13,129 ) 53,876 (29,681 )
Other income, net   1,338     600     3,364     1,673  
Income (loss) before income taxes 23,978 (12,529 ) 57,240 (28,008 )
Income tax (expense) benefit   (3,690 )   4,103     (12,704 )   9,210  
Net income (loss) $ 20,288   $ (8,426 ) $ 44,536   $ (18,798 )
Net income (loss) per share
Basic $ 1.05 $ (0.44 ) $ 2.32 $ (0.99 )
Diluted $ 0.97 $ (0.44 ) $ 2.17 $ (0.99 )
Weighted average common shares outstanding
Basic 19,303 19,081 19,212 19,055
Diluted 21,017 19,081 20,509 19,055

(in thousands)

June 30, September 30,
2018 2017
Current assets
Cash and cash equivalents $ 42,477 $ 65,675
Short-term marketable securities 230,750 157,994
Accounts receivable 57,262 10,614
Prepaid expenses and other current assets   9,404   3,536
Total current assets 339,893 237,819
Long-term marketable securities 22,272 70,038
Property and equipment, net 8,383 8,049
Deferred tax assets 7,929 10,123
Restricted cash   608   608
Total assets $ 379,085 $ 326,637
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable $ 4,902 $ 3,714
Accrued expenses and other current liabilities 9,127 7,970
Income taxes payable   -   9,298
Total current liabilities 14,029 20,982
Warrant liability - 807
Series 1 nonconvertible preferred stock 1,528 762
Other long-term liabilities   2,627   2,410
Total liabilities   18,184   24,961
Total stockholders' equity   360,901   301,676
Total liabilities and stockholders' equity $ 379,085 $ 326,637

View Comments and Join the Discussion!